Compared with PD-L1 expression, which does not predict ICIs responses such as melanoma, TMB is a more easily assessable predictive biomarker that could be incorporated in the researches of all solid malignant tumor.[48] The early progress has been made in the use of TMB to predict the responses to ICIs in cancer patients.[49,50] Evidence suggests that high TMB is an independent biomarker of ICIs response in multiple tumor types. The gene discussed is CD274; the disease is cancer.